PET/CT and MR imaging in myeloma.
Myeloma is the most common primary bone malignancy. It accounts for 10% of all hematological malignancies and 1% of all cancers. In the United States, there are an estimated 16,000 new cases and over 11,000 deaths yearly due to myeloma. Plasma cell dyscrasias manifest themselves in a variety of forms that range from MGUS (monoclonal gammopathy of undetermined significance) and smoldering myeloma that require no therapy, to the "malignant" form of multiple myeloma. The role of imaging in the management of myeloma includes: an assessment of the extent of intramedullary bone disease, detection of any extramedullary foci, and severity of the disease at presentation; the identification and characterization of complications; subsequent assessment of disease status. This review will focus on the use of PET/CT and MR imaging for myeloma patients at the time of initial diagnosis and for follow-up management, based on current reports in the literature and our practice at the Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center in Baltimore, USA.
Mulligan
Michael E
ME
Department of Radiology, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21201, USA. mmulligan@umm.edu
Badros
Ashraf Z
AZ
D001859:Bone Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D015203:Reproducibility of Results; D014057:Tomography, X-Ray Computed